bluebird bio - BLUE Stock Forecast, Price & News

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

bluebird bio Stock Performance

Shares of NASDAQ:BLUE traded up $0.41 during trading hours on Friday, reaching $6.72. The stock had a trading volume of 7,359,542 shares, compared to its average volume of 6,021,368. bluebird bio has a 1 year low of $2.87 and a 1 year high of $25.39. The firm's 50 day moving average is $4.52 and its 200-day moving average is $4.71. The stock has a market capitalization of $518.25 million, a price-to-earnings ratio of -0.81 and a beta of 1.29.

bluebird bio (NASDAQ:BLUE - Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($1.29) EPS for the quarter, beating analysts' consensus estimates of ($1.31) by $0.02. bluebird bio had a negative net margin of 2,141.34% and a negative return on equity of 130.19%. The company had revenue of $1.52 million for the quarter, compared to the consensus estimate of $6.47 million. Analysts forecast that bluebird bio will post -4.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Morgan Stanley cut their target price on shares of bluebird bio to $3.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 17th. Raymond James raised shares of bluebird bio from a "market perform" rating to an "outperform" rating and set a $8.00 target price on the stock in a research note on Tuesday, August 2nd. Wedbush cut their target price on shares of bluebird bio from $10.00 to $8.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 10th. Finally, Barclays raised shares of bluebird bio from an "underweight" rating to an "equal weight" rating and upped their target price for the stock from $3.00 to $5.00 in a research note on Friday, August 5th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $10.50.

Insider Activity

In other news, CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total value of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Jason Cole sold 7,448 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total value of $32,696.72. Following the completion of the transaction, the insider now owns 203,740 shares in the company, valued at approximately $894,418.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares of the company's stock, valued at approximately $1,084,905.09. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,364 shares of company stock worth $146,664. Corporate insiders own 2.90% of the company's stock.